GoAI
Get started
Biomea Fusion, Inc. logo

Biomea Fusion, Inc.

BMEA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.37

+$0.01 · +0.74%

Aug 21, 4:00 PM ET

BMEA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

27

Expensive

Momentum

41

Neutral

Sentiment

44

Mixed

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Michael J. Hitchcock
Listed since
Apr 16, 2021
Employees
37

Market position

Day range

Current $1.37

52-week range

Current $1.37

Open
$1.355
Previous close
$1.36
Volume
575.26K
0.52× average
Average volume
1.1M
Average daily volume
Market cap
99.05M USD
Beta
-0.3
Market reference 1
50-day average
$1.2834
+6.75% above average
200-day average
$1.3525
+1.29% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
10.54M USD
P/E (TTM)
-2.76×
P/B (TTM)
8.17×
P/S (TTM)
0×
EV / EBITDA
-0.17×
Earnings yield
-95.42%
Free cash flow yield
-108.66%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-209.11%
Return on assets
-105.51%
Return on invested capital
-166.16%

Financial health

Debt / equity
0.07×
Current ratio
5.23×

Financial statements

Income trends

Operating income

−81.31M USD+43.56%

Net income

−61.8M USD+55.36%
Income trends across reported periods−31.32M USD−72.32M USD−113.32M USD−154.32M USDOperating income, FY2021: −41.67M USDOperating income, FY2022: −83.63M USDOperating income, FY2023: −126.14M USDOperating income, FY2024: −144.07M USDOperating income, FY2025: −81.31M USDNet income, FY2021: −41.57M USDNet income, FY2022: −81.83M USDNet income, FY2023: −117.26M USDNet income, FY2024: −138.43M USDNet income, FY2025: −61.8M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −41.67M USD. Operating income FY2022 −83.63M USD. Operating income FY2023 −126.14M USD. Operating income FY2024 −144.07M USD. Operating income FY2025 −81.31M USD. Net income FY2021 −41.57M USD. Net income FY2022 −81.83M USD. Net income FY2023 −117.26M USD. Net income FY2024 −138.43M USD. Net income FY2025 −61.8M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold1.41M USD————
Gross profit−1.41M USD————
Research and development61.98M USD118.09M USD102.55M USD62.71M USD28M USD
Selling, general, and administrative19.33M USD25.99M USD23.59M USD20.92M USD13.67M USD
Operating expenses79.9M USD144.07M USD126.14M USD83.63M USD41.67M USD
Interest income1.86M USD5.64M USD8.88M USD1.81M USD100K USD
Depreciation and amortization1.41M USD1.75M USD1.52M USD691K USD249K USD
Operating income−81.31M USD−144.07M USD−126.14M USD−83.63M USD−41.67M USD
Net income−61.8M USD−138.43M USD−117.26M USD−81.83M USD−41.57M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 4 misses, 1 met estimate
Average EPS surprise
-5.08%
11 comparable reports
Latest EPS result
-0.12
Estimate -0.22 · Beat by 46.30%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.1-0.42-0.75-1.07Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -0.81, estimate -1, surprise +19.00%, Beat. Q2 2025, reported May 5, 2025: actual -0.8, estimate -0.84, surprise +4.76%, Beat. Q3 2025, reported Aug 5, 2025: actual -0.51, estimate -0.59, surprise +13.56%, Beat. Q4 2025, reported Nov 4, 2025: actual -0.27, estimate -0.26, surprise -3.85%, Miss. Q1 2026, reported Mar 24, 2026: actual -0.64, estimate -0.25, surprise -156.00%, Miss. Q2 2026, reported May 11, 2026: actual -0.17, estimate -0.24, surprise +29.17%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.12, estimate -0.223, surprise +46.30%, Beat. Q4 2026, reported Nov 3, 2026: actual —, estimate -0.21, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates6.54M4.7M2.87M1.04MQ2 '24Q1 '25
Q2 2024, reported Apr 1, 2024: actual 6.14M USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 31, 2025: actual 1.22M USD, estimate —, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$20.20

1374.45% upside
Past 12 months12-month forecastHigh $40.00Average $20.20Low $10.00

BMEA news

globenewswire.com

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

• Initiated Study to Assess the Potential Impact of the Combination of Icovamenib and Low-Dose Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health, and Metabolic Outcomes

Read source
globenewswire.com

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

SAN CARLOS, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results…

Read source
globenewswire.com

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary…

Read source
globenewswire.com

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary…

Read source
globenewswire.com

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes Late-Breaking Preclinical Findings…

Read source

BMEA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding BMEA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.48M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
741.94K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
318.31K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%

Continue in GoAI

Research BMEA

research.disclaimer